IntroducingRare intelligence for commercialization
Every other biopharma
commercialization
model is now obsolete
CG Life and The Considered have combined as a new entity where expertise and AI work as one.
Drug launches for rare, specialty, and hard-to-treat diseases demand more than traditional commercialization can deliver. They require sharper intelligence, higher scientific fluency, behavior-changing creativity, and the ability to move from insight to execution at scale without losing momentum.
To heed that call, you need world-class, big-hearted talent. People who care deeply for their clients' businesses and others' wellbeing.
The stakes have never been higher for biopharma launches. That's why CG Life and The Considered are coming together as one AI-native, integrated team. We're your purpose-built partner—an extension of your team—for navigating the complexity of this moment with clarity.
Rare intelligence for
commercialization means:
Greater Precision
Teams are hardwired to utilize AI for sharper scientific fluency, market understanding, and stakeholder insights that drive launch performance.
Greater Differentiation
Brand strategy and behavior-changing creative, fueled by human expertise and GenAI, help translate complexity into work that earns attention, trust, and action.
Greater Acceleration
Connected AI workflows and integrated execution help teams move from insight to decision to activation with greater speed and confidence.
Greater Impact
Human understanding across patient, caregiver, HCP, and advocate communities keeps commercialization connected to the people it serves.
Despite remarkable advances in science, too many therapies struggle to achieve their full potential due to commercialization strategies designed for a bygone era. For companies developing innovative therapies, success is no longer determined solely by clinical data. It depends on helping patients, caregivers, physicians, and advocacy groups understand why a new therapy matters and how it can change lives. The stakes have never been higher.
Does your next launch need a partner built for the moment?
Let's talk.
Combining deep life science expertise with an AI-native operating model, we're poised to create meaningful impact for patients and healthy growth for the biopharma brands that serve them.